Navigation Links
Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
Date:10/9/2007

LYON, France, Oct. 9 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that data from a study in mice demonstrated the potential of its patented Vaxfectin(TM) adjuvant to be used as a dose-sparing agent with a protein-based H5N1 pandemic influenza vaccine currently stockpiled by the U.S. government. Dose-sparing ability could be critical in extending limited vaccine supplies to protect the greatest number of people in the event of a pandemic influenza outbreak. Alain Rolland, Pharm.D., Ph.D., Vical's Senior Vice President of Product Development, presented the data at the World Vaccine Congress (Lyon, France, October 8 - 10).

Vaxfectin(TM)-formulated Measles DNA Vaccine

The company also announced that a measles DNA vaccine formulated with the company's Vaxfectin(TM) adjuvant elicited sustained protective levels of neutralizing antibodies in infant (6 - 10 week old) nonhuman primates confirmed by complete protection following challenge one year after intradermal vaccination, with no clinical signs of disease and no culturable virus after challenge. In May, the company announced similar results in juvenile (1 - 2 year old) nonhuman primates. Both measles studies were conducted in collaboration with Diane E. Griffin, M.D., Ph.D., Alfred and Jill Sommer Professor and Chair of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, under a grant from the Bill and Melinda Gates Foundation.

"We continue to expand the database demonstrating the dose-sparing and immunogenicity-enhancing capabilities of our Vaxfectin(TM) adjuvant," said Dr. Rolland, "as well as its potential safety and tolerability advantages. Our lead DNA vaccine candidate against H5N1
'/>"/>

SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
4. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
7. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
8. Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
9. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
10. Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...wire-FirstCall/--NuVasive,Inc.(Nasdaq: NUVA ),amed...imallydisruptivesurgicaltreatmentsforthespine,anno...vember30,2009,at5:30p.m.ET/2:30p.m.PT.Theconferenc...ntfortheCompany,sproductsandwillincludecommentsfro...n.Thedial-innumbersare1-877-407-4018fordomesticcal...
(Date:11/25/2009)...dJOHANNESBURG,November25/PRNewswire/--,iThembaPhar...cedtoday,thattheyhavesignedacollaborativeagreement...is,sworldclasscomputationalchemistryandleaddiscove...iontoprovidemedicinaland,syntheticchemistrysupport...entnetwork.iThembaPharmaceuticalsandPyxisDiscovery...
(Date:11/24/2009)...wswire/-- ,, WHAT:RomHoubens,aBelgianmanthought...wasactuallyfullyconsciousandawakeduringthattimeand...oxEyeMaxwasfeaturedinthesegmenttoillustratehowpeop...communication. ,, WHEN:GoodMorningAmerica-- Tue...ch.com ,, WHO:RomHoubenswasanengineeringstu...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2FDA Approves NovoLog 28R 29 Labeling Update 51814 1FDA Approves NovoLog 28R 29 Labeling Update 51814 2FDA Approves NovoLog 28R 29 Labeling Update 51814 3FDA Approves NovoLog 28R 29 Labeling Update 51814 4U S Students Academic Interests Tend to Wane in Middle School 51812 1U S Students Academic Interests Tend to Wane in Middle School 51812 2Michael Steele Chairman of the Republican National Committee Will Hold a Press Conference on Health Care the Republican Alternative at 9 am on Mon 51810 1
...at data,presented recently at the 17th Annual Meet...iology demonstrate that the Genous Bio-engineered ...eluting stents., Presented by Federico Piscione, ...fessor with the Federico II University of Naples,s...dicine and Cardiovascular,Sciences, the data were ...
...ion Application currently u...erapeutics, Inc. (CTI),(Nasdaq: CTIC ; MTA) today...domized phase III trial comparing OPAXIO(TM) (pacl...orelbine for the treatment of PS 2,(performance st...ll cell,lung cancer (NSCLC) in the Journal of Thor...
Other Medicine Technology:Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 2Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5
(Date:11/27/2009)..., NEUILLY-SUR-SEINE,France,Nov.27/PRNewswire/--Te...clingteamdedicatedtoethicalsportinganddevelopingth...atitwillbecomeTeamGarmin-Transitionswiththeadditio...tionsOpticalistheworld,sleadingmanufacturerofadapt...nologyinthewidestselectionofspectaclelensessuchasT...
(Date:11/27/2009)... XenaCare Holdings has announc...thritis Foundation, one of the largest nonprofit o...ublic health education. , ...aCare Holdings, Inc. (OTCBB: XCHO), a company spec...of consumer healthcare products, has announced tod...
(Date:11/27/2009)...ng rates to bring unprecedented medical, economic ... 27 (HealthDay News) -- The number of people with ...e over the next 25 years, a new study predicts. ,...1 million people with the disease, up from 23.7 mi...reating people with diabetes will triple, the stud...
(Date:11/27/2009)... Voyant Health™ announce...an) has licensed its TraumaCad Enterprise orthoped...rkflow solution. , (PRWEB...ced today that Spectrum Health (Grand Rapids, Mich...edic templating solution and its TraumaCad Extend ...
(Date:11/27/2009)... Specialist manufacturers who ...cts are saving millions of dollars by bringing in ...cess. Increasing numbers of pro-active medical man...s at the concept stage of their projects, ensuring... design processes or potentially outdated technolo...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...LLE, Pa., Dec. 21 RESPIRONICS, INC.,(Nasdaq: RES...ve merger,agreement pursuant to which Royal Philip... commence a tender offer to acquire all of the out... a,premium of approximately 31% over Respironics, ...
... study finds that most general surgeons do not dis...breast cancer treatment. The analysis shows that o...or breast conserving surgery have such discussions...nstruction has increased treatment choices for wom...
...Calif., Dec. 20 ISTA Pharmaceuticals,Inc. (Nasdaq...ed a New Drug,Application (NDA) to the U.S. Food a...ce-daily). The Company is seeking approval for Xib...opical non-steroidal anti-inflammatory compound fo...
...om Community Will Fund 20 Percent of Cost for New ...undation announced that it has reached its $50 mil...mportant philanthropic effort Sharp has ever,under...com/cgi-bin/prnh/20071220/DC10448 ), "It,s only ...
...ON, Dec. 20 Today URAC called for,comments on maj...alth Web,Site, HIPAA Privacy (Business Associate a...sociate and Covered Entity) accreditation programs...ne for public comment is Feb. 10, 2008., (LOGO: ...
...N, Va., Dec. 20 MCG Capital,Corporation (Nasdaq: ...ferred,equity investment to support the acquisitio...ld & Lamb is a medical-financial services company ...tion industry,since 2001. Having completed in exce...
Other Medicine News:Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 2Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 3Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 4Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 5Health News:Reconstruction surgery rarely discussed with breast cancer patients 2Health News:ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily) 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 3Health News:URAC Calls for Comments on Changes to Standards for Health Web Site, HIPAA Privacy and Security Accreditation Programs 2Health News:MCG Capital Invests in Gould & Lamb 2
...ested Timeter® Classic Flowmeters demonstrates...oviders and patients alike. You can see it in the ... can see it in the performance, year after year. E...d and engineered to the highest standards of perfo...
Soft-Touch Timeter® 15 LPM Dual Oxygen Flowmeter w/Y Bar & 2 Power Take Off
Soft-Touch Timeter® 15 LPM Dual Oxygen Flowmeter w/T Bar
Soft-Touch Timeter® 8 LPM Flowmeter
Medicine Products: